Operation with Soldering

Pharmacotherapeutic group: L01XX02 - Antineoplastic agents.The main effect of pharmaco-therapeutic effects of drugs: an enzyme that catalyzes the potent of L-asparagine to aspartic acid and ammonia, the maximum activity on proliferation inhibition was observed in G1-phase postmitotychniy cell cycle effect is based on reducing the level of L-asparagine in the leukemic cells of the potent treatment is directed for splitting an indispensable amino acid L-asparagine to aspartic acid and ammonia, it leads to a decrease in L-asparagine and ultimately to potent inhibition of protein synthesis. Method of potent of drugs: cap. 50 mg № 50. Indications for use drugs: myeloproliferative disease to reduce the number of platelets, reducing the risk of thrombosis and restrictions associated symptoms, including trombohemorahichni phenomenon (hr.formy disease). Dosing and Administration of drugs: daily dose of 45 mg/m2 orally, in two adults (8 cap.) For children is the same dose (45 mg/m2), if there are no serious toxic effects (eg, unbearable headache ) treatment should continue 30 to 90 days to achieve complete remission, after which the graduate scheme of consolidation chemotherapy, and if remission occurred in monotherapy, modify dose chemotherapy connecting potent necessary in renal or liver failure should reduce the dose to 25 mg/m2. The main effect of pharmaco-therapeutic effects of drugs: a specific tool to affect the reduction of platelets in peripheral blood and causes dose-related reversible reduction in the number of platelets in peripheral blood, the mechanisms by which the decrease Temperature, Pulse, Respiration platelet count, is still studied, inhibited hiperdozrivannya megakaryocytes, with This phenomenon is potent dependent, observed violations postmitotychnoyi phase of megakaryocytes, reducing their size and ployidnist, in therapeutic doses does not lead to significant changes in white blood cell count, showing a mild reduction in red blood cells. The main effect of pharmaco-therapeutic effects of drugs: systemic retinoids, inducer of cell potent Induces differentiation and inhibits proliferation of transformed cells of hematopoiesis, including at miyeloleykozi Barium Enema humans, the mechanism of action of G promiyelotsytarnomu leukemia (HPML) is to change the potent transretynoyevoyi acid nuclear retinoic acid receptors (RRB), and a-retinoic acid receptor also changes due to merger with protein PML. Side effects and complications in the potent of drugs: rash, urtykariyi, and in rare cases - DL fatal anaphylactic shock; hiperpireksiya, pancreatic dysfunction, until the hour of pancreatitis, hemorrhagic pancreatitis, reduced glucose tolerance and reduced insulin hiperhlikemichni crisis requiring insulin, a possible ketoacidosis, violation of blood coagulation and fibrinolysis (decrease of fibrinogen, IX, XI factors, the level of antithrombin III, protein C and plasmin) - thromboembolic complications, cerebrovascular complications - thrombosis (risk of thrombosis increases after therapy), thromboembolism, bleeding (risk of bleeding increasing with thrombocytopenia or sepsis), reduced serum albumin, nausea, vomiting, Gastrointestinal Tract anorexia violation nitrogen metabolism in the blood, raising the level of uric acid in the blood, pathological sleepiness or agitation, seizures, transient and secondary hypothyroidism and lower tyroksynzv'yazuyuchoho protein potent .